Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease
IntroductionGraves’ disease is an autoimmune disorder caused by auto-antibodies against the thyroid stimulating hormone receptor (TSHR). Overstimulation of the TSHR induces hyperthyroidism and thyroid eye disease (TED) as the most common extra thyroidal manifestation of Graves’ disease. In TED, the...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1252727/full |
| _version_ | 1827808874987520000 |
|---|---|
| author | Anne Gulbins Mareike Horstmann Simone Keitsch Matthias Soddemann Barbara Wilker Gregory C. Wilson Ryan Zeidan Gary D. Hammer Anke Daser Nikolaos E. Bechrakis Gina-Eva Görtz Anja Eckstein |
| author_facet | Anne Gulbins Mareike Horstmann Simone Keitsch Matthias Soddemann Barbara Wilker Gregory C. Wilson Ryan Zeidan Gary D. Hammer Anke Daser Nikolaos E. Bechrakis Gina-Eva Görtz Anja Eckstein |
| author_sort | Anne Gulbins |
| collection | DOAJ |
| description | IntroductionGraves’ disease is an autoimmune disorder caused by auto-antibodies against the thyroid stimulating hormone receptor (TSHR). Overstimulation of the TSHR induces hyperthyroidism and thyroid eye disease (TED) as the most common extra thyroidal manifestation of Graves’ disease. In TED, the TSHR cross talks with the insulin-like growth factor 1 receptor (IGF-1R) in orbital fibroblasts leading to inflammation, deposition of hyaluronan and adipogenesis. The bone marrow may play an important role in autoimmune diseases, but its role in Graves’ disease and TED is unknown. Here, we investigated whether induction of experimental Graves’ disease and accompanying TED involves bone marrow activation and whether interference with IGF-1R signaling prevents this activation.ResultsImmunization of mice with TSHR resulted in an increase the numbers of CD4-positive T-lymphocytes (p ≤0.0001), which was normalized by linsitinib (p = 0.0029), an increase of CD19-positive B-lymphocytes (p= 0.0018), which was unaffected by linsitinib and a decrease of GR1-positive cells (p= 0.0038), which was prevented by linsitinib (p= 0.0027). In addition, we observed an increase of Sca-1 positive hematopietic stem cells (p= 0.0007) and of stromal cell-derived factor 1 (SDF-1) (p ≤0.0001) after immunization with TSHR which was prevented by linsitinib (Sca-1: p= 0.0008, SDF-1: p ≤0.0001). TSHR-immunization also resulted in upregulation of CCL-5, IL-6 and osteopontin (all p ≤0.0001) and a concomitant decrease of the immune-inhibitory cytokines IL-10 (p= 0.0064) and PGE2 (p ≤0.0001) in the bone marrow (all p≤ 0.0001). Treatment with the IGF-1R antagonist linsitinib blocked these events (all p ≤0.0001). We further demonstrate a down-regulation of arginase-1 expression (p= 0.0005) in the bone marrow in TSHR immunized mice, with a concomitant increase of local arginine (p ≤0.0001). Linsitinib induces an upregulation of arginase-1 resulting in low arginase levels in the bone marrow. Reconstitution of arginine in bone marrow cells in vitro prevented immune-inhibition by linsitinib.ConclusionCollectively, these data indicate that the bone marrow is activated in experimental Graves’ disease and TED, which is prevented by linsitinib. Linsitinib-mediated immune-inhibition is mediated, at least in part, by arginase-1 up-regulation, consumption of arginine and thereby immune inhibition. |
| first_indexed | 2024-03-11T22:34:59Z |
| format | Article |
| id | doaj.art-90c3d0dc549e442cbf551959731928f5 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-11T22:34:59Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-90c3d0dc549e442cbf551959731928f52023-09-22T19:10:28ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-09-011410.3389/fendo.2023.12527271252727Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye diseaseAnne Gulbins0Mareike Horstmann1Simone Keitsch2Matthias Soddemann3Barbara Wilker4Gregory C. Wilson5Ryan Zeidan6Gary D. Hammer7Anke Daser8Nikolaos E. Bechrakis9Gina-Eva Görtz10Anja Eckstein11Molecular Ophthalmology, Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, GermanyMolecular Ophthalmology, Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, GermanyDepartment of Molecular Biology, University of Duisburg-Essen, Essen, GermanyDepartment of Molecular Biology, University of Duisburg-Essen, Essen, GermanyDepartment of Molecular Biology, University of Duisburg-Essen, Essen, GermanyDepartment of Surgery, College of Medicine, University of Cincinnati, Cincinnati, OH, United StatesSling Therapeutics Inc., Ann Arbor, MI, United StatesEndocrine Oncology Program, University of Michigan, Ann Arbor, MI, United StatesDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Essen, GermanyDepartment of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, GermanyMolecular Ophthalmology, Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, GermanyMolecular Ophthalmology, Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, GermanyIntroductionGraves’ disease is an autoimmune disorder caused by auto-antibodies against the thyroid stimulating hormone receptor (TSHR). Overstimulation of the TSHR induces hyperthyroidism and thyroid eye disease (TED) as the most common extra thyroidal manifestation of Graves’ disease. In TED, the TSHR cross talks with the insulin-like growth factor 1 receptor (IGF-1R) in orbital fibroblasts leading to inflammation, deposition of hyaluronan and adipogenesis. The bone marrow may play an important role in autoimmune diseases, but its role in Graves’ disease and TED is unknown. Here, we investigated whether induction of experimental Graves’ disease and accompanying TED involves bone marrow activation and whether interference with IGF-1R signaling prevents this activation.ResultsImmunization of mice with TSHR resulted in an increase the numbers of CD4-positive T-lymphocytes (p ≤0.0001), which was normalized by linsitinib (p = 0.0029), an increase of CD19-positive B-lymphocytes (p= 0.0018), which was unaffected by linsitinib and a decrease of GR1-positive cells (p= 0.0038), which was prevented by linsitinib (p= 0.0027). In addition, we observed an increase of Sca-1 positive hematopietic stem cells (p= 0.0007) and of stromal cell-derived factor 1 (SDF-1) (p ≤0.0001) after immunization with TSHR which was prevented by linsitinib (Sca-1: p= 0.0008, SDF-1: p ≤0.0001). TSHR-immunization also resulted in upregulation of CCL-5, IL-6 and osteopontin (all p ≤0.0001) and a concomitant decrease of the immune-inhibitory cytokines IL-10 (p= 0.0064) and PGE2 (p ≤0.0001) in the bone marrow (all p≤ 0.0001). Treatment with the IGF-1R antagonist linsitinib blocked these events (all p ≤0.0001). We further demonstrate a down-regulation of arginase-1 expression (p= 0.0005) in the bone marrow in TSHR immunized mice, with a concomitant increase of local arginine (p ≤0.0001). Linsitinib induces an upregulation of arginase-1 resulting in low arginase levels in the bone marrow. Reconstitution of arginine in bone marrow cells in vitro prevented immune-inhibition by linsitinib.ConclusionCollectively, these data indicate that the bone marrow is activated in experimental Graves’ disease and TED, which is prevented by linsitinib. Linsitinib-mediated immune-inhibition is mediated, at least in part, by arginase-1 up-regulation, consumption of arginine and thereby immune inhibition.https://www.frontiersin.org/articles/10.3389/fendo.2023.1252727/fullbone marrowlinsitinibautoimmunityinflammationsmall molecule IGF-1R antagonist GD: Graves’ diseasethyroid eye disease (TED) |
| spellingShingle | Anne Gulbins Mareike Horstmann Simone Keitsch Matthias Soddemann Barbara Wilker Gregory C. Wilson Ryan Zeidan Gary D. Hammer Anke Daser Nikolaos E. Bechrakis Gina-Eva Görtz Anja Eckstein Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease Frontiers in Endocrinology bone marrow linsitinib autoimmunity inflammation small molecule IGF-1R antagonist GD: Graves’ disease thyroid eye disease (TED) |
| title | Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease |
| title_full | Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease |
| title_fullStr | Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease |
| title_full_unstemmed | Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease |
| title_short | Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease |
| title_sort | potential involvement of the bone marrow in experimental graves disease and thyroid eye disease |
| topic | bone marrow linsitinib autoimmunity inflammation small molecule IGF-1R antagonist GD: Graves’ disease thyroid eye disease (TED) |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1252727/full |
| work_keys_str_mv | AT annegulbins potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT mareikehorstmann potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT simonekeitsch potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT matthiassoddemann potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT barbarawilker potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT gregorycwilson potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT ryanzeidan potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT garydhammer potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT ankedaser potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT nikolaosebechrakis potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT ginaevagortz potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease AT anjaeckstein potentialinvolvementofthebonemarrowinexperimentalgravesdiseaseandthyroideyedisease |